An advisory committee of the U.S. Food and Drug Administration (FDA) has supported the registration of Moderna's new mRNA vaccine against seasonal flu. This was reported by Qazaqyia.kz citing Kursiv Media.
If the FDA approves the drug, mFlusiva would become the first mRNA vaccine against seasonal flu on the US market.
The expert panel unanimously determined that the benefits of mFlusiva outweigh potential risks for both people aged 50 to 64 and those 65 and older. The FDA must now make a final decision. The regulator's verdict is expected before the start of the flu vaccination season.
The vaccine is based on the same mRNA technology previously used to create COVID-19 vaccines. According to developers, this approach allows for faster updates of the vaccine composition to match circulating flu virus strains and accelerates vaccine production.
In clinical trials, the vaccine showed higher efficacy compared to standard flu shots among people aged 50-64. In participants over 65, the drug elicited a strong immune response, which formed the basis for recommending its use in this age group.
However, additional studies are needed for a final assessment of efficacy. Moderna has already committed to conducting a large study involving hundreds of thousands of people.
Earlier, Kursiv Health shared a vaccination calendar. Which vaccines to get and when — read our article.
If the article causes you anxiety, discuss it with an artificial psychologist.